1. Chernushkin K, Loewen P, de Lemos J, Aulakh A, Jung J, Dahri K. Diagnostic reasoning by hospital pharmacists: assessment of attitudes, knowledge, and skills. Can J Hosp Pharm 2012;65:258–64. 

2. Barry AR, Loewen P, de Lemos J, Lee KG. Reasons for non-use of proven pharmacotherapeutic interventions: systematic review and framework development. J Eval Clin Pract 2012;18:49–55. 

3. Buna DK, McGloin R, Loewen P, Thornhill AK, Dillon ED, Hawkes J. Survey of graduates of the british columbia pharmacy practice residency programs, 1973-2009. Can J Hosp Pharm 2011;64:419–25. 

4. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann. Hematol. 2011;90:1191–200. 

5. Bruchet N, Loewen P, de Lemos J. Improving the quality of clinical pharmacy services: a process to identify and capture high-value "quality actions". Can J Hosp Pharm 2011;64:42–7. 

6. Schwenger EM, Tejani AM, Loewen P. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database of Systematic Reviews 2010;

7. Hohl CM, Zed PJ, Brubacher JR, Abu-Laban RB, Loewen P, Purssell RA. Do emergency physicians attribute drug-related emergency department visits to medication-related problems? Ann Emerg Med 2010;55:493–4. 

8. Mountford CM, Lee T, de Lemos J, Loewen P. Quality and usability of common drug information databases. Can J Hosp Pharm 2010;63:130–7. 

9. Loewen P, Merrett F, LEMOS JD. Pharmacists' perceptions of the impact of care they provide. Pharmacy Practice  2010;

10. Loewen P. Should a Process be Developed to Recognize “Pharmacy Practice Residency Equivalency” for Pharmacists with Substantial Clinical Experience Who Have Not …. Can J Hosp Pharm 2010;63:30–1. 

11. Barry AR, Loewen P, de Lemos J, Lee KG. Reasons for Non-use of Proven Interventions for Hospital Inpatients: Pharmacists' Perspectives. Can J Hosp Pharm 2009;62:381–5. 

12. Loewen P. Should the Window for Intravenous Administration of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke be Extended to 4.5 Hours? Can J Hosp Pharm 2009;62:248–51. 

13. Huang C, Loewen P, Pelletier T, Slater J, Chung M. Implementation of proven interventions in general medical inpatients: development and evaluation of a new quality indicator for drug therapy. Qual Saf Health Care 2008;17:269–74. 

14. Zed PJ, Abu-Laban RB, Balen RM, Loewen P, Hohl CM, Brubacher JR, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008;178:1563–9. 

15. Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb. Haemost. 2007;98:980–7. 

16. McCormack JP, Loewen P. Adding “value” to clinical practice guidelines. Can Fam Physician 2007;53:1326–7. 

17. Patel K, Loewen P, Wilbur K. A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients. The Canadian Journal of Hospital … 2006;

18. Saran MK, Loewen PS, Zed PJ. Opportunities for optimizing pantoprazole therapy in patients with acute upper gastrointestinal bleeding. Hospital Pharmacy 2006;

19. McCormack JP, Loewen P. The other side of the bezafibrate infarction prevention trial data. Arch. Intern. Med. 2005;165:2431–2–authorreply2432. 

20. Raybardhan S, Balen RM, Partovi N, Loewen P, Liu G, Jewesson PJ. Documenting drug-related problems with personal digital assistants in a multisite health system. Am J Health Syst Pharm 2005;62:1782–7. 

21. McCormack JP, Loewen P, Jewesson PJ. Dissemination of results needs to be tracked as well as the funding is. BMJ 2005;331:456. 

22. McCormack JP, Loewen P. Misplaced allegations. CMAJ 2004;170:1207–7. 

23. Sprague DA, Loewen P, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother 2004;38:313–9. 

24. Loewen P, Lamb S, Clugston P. Randomized, double-blind trial of dolasetron versus droperidol for prophylaxis of postoperative nausea and vomiting in patients undergoing TRAM flap breast reconstruction surgery. Ann Plast Surg 2003;51:472–7. 

25. Zed PJ, Rowe BH, Loewen P, Abu-Laban RB. Systematic reviews in emergency medicine: Part II. Critical appraisal of review quality, data synthesis and result interpretation. CJEM 2003;5:406–11. 

26. Zed PJ, Rowe BH, Loewen P, Abu-Laban RB. Systematic reviews in emergency medicine: Part I. Background and general principles for locating and critically appraising reviews. CJEM 2003;5:331–5. 

27. Sprague DA, Loewen P. Bedside calculation of stroke risk in patients with atrial fibrillation. Am J Health Syst Pharm 2003;60:427–9. 

28. Zed PJ, Loewen P, Jewesson PJ. A response to the ACP-ASIM position paper on pharmacist scope of practice. Am J Health Syst Pharm 2002;59:1453–6. 

29. Loewen P. Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. CJEM 2002;4:268–75. 

30. Loewen P. Anti-emetics in development. Expert Opin. Investig. Drugs 2002;11:801–5. 

31. Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001;35:1528–34. 

32. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001;19:927–36. 

33. Loewen PS, Marra CA, Zed PJ. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting. Can J Anaesth 2000;47:1008–18. 

34. Frighetto L, Loewen P, Dolman J, Marra CA. Cost-effectiveness of prophylactic dolasétron or droperidolvs rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. Can J Anesth/J Can Anesth 1999;46:536–43. 

35. Loewen PS, Marra CA, Marra F. Systematic review of the treatment of early Lyme disease. Drugs 1999;57:157–73. 

36. Loewen P, Marra F, Marra CA. Influence of the Methods of Reporting Clinical Trial Results on Pharmacists' Willingness to Recommend Drug Therapy. Can J Hosp Pharm 1999;52:145–9. 

37. Zed PJ, Loewen PS, Robinson G. Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 1999;33:61–72. 

38. Esmail ZN, Loewen PS. Losartan as an alternative to ACE inhibitors in patients with renal dysfunction. Ann Pharmacother 1998;32:1096–8. 

39. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and ASA therapy: a systematic review of the literature and update of guidelines. Canadian Journal of Cardiology 1998;14:717–26.